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Background. Invasive fungal infections (IFIs) are life-threatening complications in neutropenic patients with
hematological malignancies. Because early diagnosis of IFI is difficult, new noninvasive, culture-independent di-
agnostic tools are needed to improve clinical management. Recent studies have reported that detection of 1,3-b-
D-glucan (BG) antigenemia may be useful for diagnosis of IFI. The aim of the present prospective study was to
evaluate the usefulness of monitoring BG in patients undergoing chemotherapy for acute leukemia.
Methods. BG antigenemia was measured by a colorimetric assay twice weekly in the absence of fever and daily
in the presence of fever. IFIs were classified according to the criteria of the European Organization for Research
and Treatment of Cancer/Mycoses Study Group.
Results. During 190 consecutive neutropenic episodes (median duration, 22 days; range, 7–113 days) in 95
patients, 30 proven or probable IFIs (13 aspergillosis, 15 candidiasis, and 2 mixed IFIs) were diagnosed. Sensitivity,
specificity, positive predictive value, negative predictive value, and efficiency of 2 consecutive BG values 7 pg/
mL for diagnosis of proven or probable IFI was 0.63 (95% confidence interval, 0.44–0.79), 0.96 (95% confidence
interval, 0.89–0.98), 0.79 (95% confidence interval, 0.57–0.92), 0.91 (95% confidence interval, 0.84–0.95), and
0.89, respectively. The time interval between onset of fever as first sign of IFI and BG antigenemia was significantly
shorter than the time to diagnosis of IFI by clinical, microbiological, radiological, and/or histopathological criteria
( ). BG values 150 pg/mL were observed in only 2 patients, both of whom experienced failure of antifungalP ! .001
therapy.
Conclusion. Monitoring of BG antigenemia is a useful noninvasive method for early diagnosis of IFI in patients
with acute leukemia.
Diagnosis of invasive aspergillosis (IA) and invasive
candidiasis (IC) in acute leukemic patients is challeng-
ing because of nonspecific clinical presentation, poor
diagnostic yield of cultures, difficulty in obtaining sam-
ples of infected tissues, and nonspecificity and delay of
radiological imaging (e.g., CT scan). Late diagnosis and
antifungal therapy are associated with severe morbidity
and high mortality [1, 2]. Prophylaxis may prevent IFI
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but implies the exposure of large numbers of patients
to antifungals [3–5]. Empirical antifungal therapy is the
standard of care for suspected IFI in neutropenic pa-
tients with persistent fever not responding to antibac-
terial therapy [6]. Experts have challenged the appro-
priateness of this strategy, because it is based on a
nonspecific clinical sign that cannot differentiate IFI
from other conditions [7, 8]. New culture-independent,
rapid, and specific tools for early noninvasive diagnosis
of IFI are needed to promptly identify patients who
need antifungal therapy [9–11]. Studies of tests de-
tecting Aspergillus antigens (galactomannan) or Can-
dida antigens and/or antibodies (mannan and/or an-
timannan) have reported variable results in neutropenic
patients [12–16].
1,3-b-d-Glucan (BG) is a fungal cell wall component
circulating in the blood of patients with IA, IC, and
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Table 1. Patient demographic characteristics, clinical characteristics, and
febrile episodes.
Characteristic Finding
No. of patients 95
Sex, male/female 58/37
Age, years 57 (19–77)
No. of hematological malignancies, AML/ALL 80/15
Neutropenic episodes
Total no. of episodes 190
Chemotherapy, induction-reinduction/consolidation 109/81
Median episodes per patient (range) 2 (1–4)
Duration of neutropenia, median days (range) 22 (7–113)
Febrile episodes
Total no. of episodes 337a
Microbiologically documented infection with bacteremia 103 (31)
Microbiologically documented infection without bacteremia 22 (7)
Clinically documented infection 123 (36)
Unexplained fever 89 (26)
IFI
Total no. of episodes 62b
Proven IFI 9 (15)
Aspergillosis, no. of episodes 5
Candidiasis, no. of episodes 4
Probable IFI 23 (37)
Aspergillosis, no. of episodes 10
Candidiasis, no. of episodes 13
Possible IFI 30 (48)
NOTE. Data are no. (%) of episodes, unless otherwise specified. ALL, acute lympho-
blastic leukemia; AML, acute myeloid leukemia; IFI, invasive fungal infection.
a Median of 2 febrile episodes per neutropenic episode (range, 0–4 febrile episodes).
b Includes 2 patients with 2 consecutive IFIs during the same neutropenic episode and
2 patients with 2 different IFIs during 2 consecutive neutropenic episodes.
other IFIs [17–19]. BG assays based on activation of factor G
of the coagulation cascade of horseshoe crabs have been studied
in hematological patients [19–23]. These observations have
shown promising diagnostic performances in proven and/or
probable IFI. False-positive results have been reported in pa-
tients exposed to products contaminated by BG or after en-
vironmental contaminations during analytical processing [24–
28]. We prospectively assessed the usefulness of monitoring BG
in leukemic patients by a colorimetric assay.
PATIENTS AND METHODS
Patients. Ninety-five of 100 consecutive adult patients with
acute myeloid or lymphoblastic leukemia hospitalized for mye-
loablative chemotherapy in a single hospital during 2002–2006
gave written informed consent for inclusion in the study. The
patients were studied throughout each hospital stay. Demo-
graphic characteristics, clinical characteristics, investigations,
and antimicrobial therapy were prospectively recorded. The
study was approved by the institutional ethics committee.
Clinical management. Patients were hospitalized in posi-
tive-pressure, high-efficiency particulate air–filtered isolation
rooms. Semiquantitative cultures of mouth, stool, and urine
specimens were obtained twice weekly for monitoring Candida
colonization (i.e., detection of any growth) [29]. Patients with
mucositis and documented oral and/or gastrointestinal tract
colonization received fluconazole prophylaxis (400 mg/day)
during neutropenia. The initial diagnostic work-up of febrile
neutropenic patients included blood and urine cultures and
chest radiography. Empirical antibacterial treatment was
promptly initiated according to international guidelines [6].
Follow-up included daily clinical examination and microbio-
logical and other clinically indicated investigations (e.g., CT
scan and tissue biopsy). Modifications of antibacterial therapy
and addition of antifungal therapy were based on clinical course
(persistent fever 172 h and site of infection) and the results of
diagnostic procedures [6].
Definitions. Neutropenia was defined as a neutrophil count
!500 cells/mm3 [30]. In an individual patient, a new neutro-
penic episode was defined as a period of neutropenia after a
distinct cycle of chemotherapy. A febrile episode was defined
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Table 2. Assessment of different 1,3-b-d-glucan (BG) cutoff values for either a single positive test result or 2
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3 977 (31) 30 (100) 58 (96) 81 (72) 29 (97) 52 (87) 55 (49)
5 499 (16) 25 (83) 44 (73) 45 (40) 23 (77) 37 (62) 19 (17)
7 335 (11) 20 (67) 34 (57) 28 (25) 19 (63) 22 (37) 5 (4)
9 234 (7) 16 (53) 24 (40) 15 (13) 15 (50) 18 (30) 3 (3)
11 177 (6) 15 (50) 19 (32) 12 (11) 12 (40) 15 (25) 1 (1)
a Includes 2 patients with 2 consecutive IFIs during the same neutropenic episode and 1 patient with Pneumocystis jiroveci pneumonia
and proven invasive aspergillosis during the same neutropenic episode.
as 2 measurements of temperature 38C over 12 h or 1 mea-
surement 38.5C [31, 32]. A period of 72 h with temper-
ature !38C was required to distinguish a new febrile episode
[31, 32]. The etiology of fever was classified as microbiologically
documented infection with or without bacteremia, clinically
documented infection, or unexplained fever, according to the
definitions of the International Immunocompromised Host So-
ciety [30]. Diagnosis of proven, probable, or possible IFI was
based on clinical, microbiological (including galactomannan
assay), radiological, and histopathological criteria, according to
European Organization for Research and Treatment of Cancer/
Mycoses Study Group (EORTC/MSG) definitions [33]. Two
independent senior radiologists who were blind to clinical di-
agnosis reviewed all high-resolution CT scans: (1) major ra-
diological signs were halo sign, air-crescent sign, or cavity
within area of consolidation; (2) minor radiological signs were
any new infiltrate not fulfilling major criteria or pleural effu-
sion; and (3) probable hepatosplenic IC was defined by small,
target-like abscesses of liver and/or spleen in intravenous con-
trast-enhanced CT [33]. Response to antifungal therapy was
defined by defervescence, clinical resolution or improvement,
and radiological stabilization or improvement.
Blood sampling. Blood samples were collected twice weekly
as long as the patient remained afebrile. For each febrile episode,
blood was sampled at fever onset and on days 1–4, 7, 10, and
14. Follow-up included twice-weekly blood sampling until oc-
currence of a subsequent febrile episode or hospital discharge.
Blood samples were collected in sterile tubes containing lith-
ium-heparin (Monovette) and were centrifuged (2000 g for 10
min at 4C). Plasma specimens were frozen at 80C.
BG assay. BG was measured by a colorimetric assay (Wako)
[34]. Five-microliter plasma samples were pretreated (for 15
min at 75C) with 45 mL of a solution containing 0.01% Triton
X-100, 4 mM sodium periodate, and 2 mM NaOH in a 96-
well microplate. Fifty microliters of the reagent solution con-
taining the endotoxin-insensitive ameboecyte lysate of the
horseshoe crab Tachypleus tridentatus and the substrate for the
horseshoe crab’s clotting enzyme—t-Boc-Thr-Gly-Arg-(N-
ethyl-N-hydroxyethyl-phenylene-diamine)—were added and
incubated (for 30 min at 37C). One hundred microliters of
coloring reagent (2.7% sodium dodecyl sulfate, 4.5 mM N,N-
diethylaniline hydrochloride, and 91 mM orthoperiodic acid)
were added; absorbance was measured at 730–650 nm. The
plasma BG concentration was calculated by a linear calibration
curve over the analytical range 1.2–120 pg/mL [34]. Intra-assay
and interassay accuracy and coefficient of variation were 85%–
115% and !7%, respectively [34]. BG was stable for 136 months
in plasma stored at80C. BG values !3 pg/mL were measured
in plasma of 72 (96%) of 75 healthy control subjects. No an-
alytical interference with BG measurement was detected while
testing commonly used antifungal and antibacterial agents [34].
Laboratory measurements were performed by technicians blind
to diagnosis of IFI. BG results were not available for clinical
management or classification of IFI.
Analysis of BG results. The primary analysis of the diag-
nostic performance of BG was performed per neutropenic ep-
isode in proven or probable IFI (true positive) versus no IFI
(true negative). The performance was assessed by calculation
of the sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), likelihood ratio (LR) of pos-
itive and negative [(1 sensitiv-[sensitivity/(1 specificity)]
ity)/specificity] results, and efficiency [(true positives + true
negatives)/all tests]. A receiver operating characteristic (ROC)
curve was obtained by plotting the false-positive rate (1spec-
ificity) against the true-positive rate (sensitivity) over the range
of cutoff values 3–11 pg/mL. The performances of a single or
2 consecutive BG values above a given cutoff were compared.
Secondary analyses of BG performance were done (1) in neu-
1,3-b-d-Glucan for Diagnosis of Mycosis • CID 2008:46 (15 March) • 881
Figure 1. Receiver operating characteristic curve of 1,3-b-d-glucan
(BG) antigenemia for diagnosis of invasive fungal infections with use of
2 consecutive positive BG values in proven or probable IFI. BG cutoff
values are indicated at each point of the curve. The diagnostic perfor-
mance is summarized in table 3. AUC, area under the curve.
Table 3. Diagnostic performance of 2 consecutive 1,3-b-d-glucan (BG) values above different cutoff values in proven and probable

















3 0.97 (0.81–1) 0.51 (0.42–0.61) 0.35 (0.25–0.46) 0.98 (0.9–1) 1.99 (1.62–2.43) 0.06 (0.01–0.45) 60.8
5 0.77 (0.57–0.89) 0.83 (0.75–0.89) 0.55 (0.39–0.7) 0.93 (0.86–0.97) 4.56 (2.89–7.19) 0.28 (0.15–0.54) 81.8
7 0.63 (0.44–0.79) 0.96 (0.89–0.98) 0.79 (0.57–0.92) 0.91 (0.84–0.95) 14.31 (5.82–35.17) 0.38 (0.24–0.61) 88.8
9 0.50 (0.32–0.68) 0.97 (0.92–0.99) 0.83 (0.58–0.96) 0.88 (0.81–0.93) 18.83 (5.83–60.83) 0.51 (0.36–0.73) 87.4
11 0.40 (0.23–0.59) 0.99 (0.94–1) 0.92 (0.62–0.1) 0.86 (0.79–0.91) 45.2 (6.12–333.94) 0.61 (0.45–0.81) 86.7
NOTE. See the receiver operating characteristic curve in figure 1. LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
tropenic episodes with proven, probable, or possible IFI, ac-
cording to the standard methodology used in recent studies of
new diagnostic markers in hematological patients [12, 13, 21],
(2) per febrile episode (on the basis of BG obtained within 72
h before fever onset), and (3) in patients with documented
bacterial bloodstream infection without concomitant IFI.
The time elapsed between fever onset as first sign of IFI and
positive BG, diagnosis of IFI by EORTC/MSG criteria, and
minor or major radiological criteria of IFI were compared with
the paired Friedman rank test (multigroup comparison) and
the paired Wilcoxon signed-rank test (2-group comparison).
Nonpaired continuous variables were compared by the Mann-
Whitney rank sum test. The level of 2-sided statistical signifi-
cance was .05. The BG kinetics according to the response to
antifungal therapy were described in patients with a 110-day
follow-up.
RESULTS
Clinical characteristics. One hundred ninety episodes of neu-
tropenia (median duration, 22 days; range, 7–113 days) were
studied in 95 adult patients undergoing myeloablative che-
motherapy for acute leukemia. An IFI was diagnosed in 60
neutropenic episodes (9 proven, 21 probable, and 30 possible),
no IFI occurred in 113, and 17 neutropenic episodes were
excluded from analysis (14 follow-up cases of IFI diagnosed
during a previous neutropenic episode and 3 with Pneumocystis
jiroveci pneumonia, which is not considered to be an IFI in
EORTC/MSG definitions). Patient demographic characteristics,
clinical characteristics, febrile episodes, and classification of IFI
are shown in table 1. Proven cases included 5 pulmonary IA
(4 A. fumigatus and 1 Aspergillus species) and 4 IC (3 with
hepatosplenic involvement and skin dissemination, including
2 with C. tropicalis and 1 with C. humicola, and 1 with C.
norvegensis candidemia). Probable cases included 10 with pul-
monary IA and 13 with hepatosplenic IC. Possible cases in-
cluded 30 pulmonary infections. Candida colonization was pre-
sent in 70% (21 of 30) of the neutropenic episodes involving
proven or probable IFI, 67% (40 of 60) of those involving
proven, probable, or possible IFI, and 60% (68 of 113) of those
that did not involve IFI. Fluconazole prophylaxis was used in
20% (6 of 30), 17% (10 of 60), and 26% (29 of 113) of episodes,
respectively.
Diagnostic performance of BG. BG was measured in 3156
serum samples (median samples per neutropenic episode, 16;
range, 3–49). BG results in neutropenic episodes with proven
or probable IFI, proven, probable, or possible IFI, and without
IFI are shown in table 2. With use of a single BG value for the
primary analysis per neutropenic episode in proven or probable
IFI, the highest test efficiency (81%) was obtained with a cutoff
value 11 pg/mL; the sensitivity, specificity, PPV, and NPV
were 0.50 (95% CI, 0.32–0.68), 0.89 (95% CI, 0.82–0.94), 0.56
(95% CI, 0.36–0.74), and 0.87 (95% CI, 0.79–0.92), respectively.
The diagnostic performance of BG with use of 2 consecutive
values above different BG cutoff values in proven or probable
IFI is shown in table 3. The corresponding ROC curve is il-
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Figure 2. Time elapsed between onset of fever as first sign of invasive fungal infections (IFIs) and diagnosis of proven or probable IFIs, according
to European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC) criteria, documentation of radiological criteria of
IFI, and 2 consecutive 1,3-b-d-glucan antigenemia measurements 7 pg/mL (2  7 pg/mL). Each time point represents a single IFI episode.
Horizontal bars, median values.
Figure 3. Kinetics of 1,3-b-d-glucan (BG) antigenemia in patients with
2 BG measurements 7 pg/mL and 110-day follow-up who responded
or did not respond to antifungal therapy.
lustrated in figure 1. The best diagnostic performance of BG
was obtained with 2 consecutive samples with BG values 7
pg/mL; sensitivity, specificity, PPV, NPV, and efficiency were
0.63 (95% CI, 0.44–0.79), 0.96 (95% CI, 0.89–0.98), 0.79 (95%
CI, 0.57–0.92), 0.91 (95% CI, 0.84–0.95), and 0.89, respectively.
The performance of 2 BG values 7 pg/mL was similar for IA
and IC (sensitivity, specificity, PPV, and NPV were 0.60, 0.96,
0.64, and 0.95, respectively, for IA and 0.59, 0.96, 0.67, and
0.94, respectively, for IC). Negative results (absence of 2 BG
measurements 7 pg/mL) were observed in 11 (37%) of 30
cases of proven or probable IFI, as follows: 2 cases of proven
IC (1 case of C. humicola disseminated IC and 1 case of C.
norvegensis candidemia), 5 cases of probable IC (hepatosplenic
lesions), 2 cases of proven pulmonary IA (histopathologically
proven without signs of vascular invasion), and 2 probable cases
of pulmonary IA (in patients with major radiological signs).
Of 113 neutropenic episodes in patients without IFI, 28 (25%)
had a single sample with BG 7 pg/mL, and only 5 (4%) had
2 samples with BG 7 pg/mL (all patients were colonized
by Candida species, 2 with oral mucositis, and 3 with enter-
ocolitis; all patients received empirical antifungal therapy for
persistent fever).
In the secondary analysis per neutropenic episodes with
proven, probable, or possible IFI, the sensitivity, specificity,
PPV, and NPV of 2 consecutive BG values7 pg/mL were 0.37
(95% CI, 0.25–0.50), 0.96 (95% CI, 0.89–0.98), 0.81 (95% CI,
0.61–0.93), and 0.74 (95% CI, 0.84–0.95), respectively. In the
secondary analysis per febrile episodes in patients with proven
or probable IFI, the sensitivity, specificity, PPV, and NPV of 2
consecutive BG values 7 pg/mL were 0.60 (95% CI, 0.29–
0.65), 0.97 (95% CI, 0.93–0.99), 0.74 (95% CI, 0.49–0.90), and
0.91 (95% CI, 0.85–0.95), respectively. Of note, only 2 (2%)
of 93 febrile episodes with documented bacteremia without
concomitant IFI had 2 BG measurements 7 pg/mL.
Time to diagnosis of IFI. In patients with proven or prob-
able IFI and 2 BG measurements 7 pg/mL, the median time
elapsed between fever onset as first sign of IFI and first BG
level 7 pg/mL was 0.5 days (range, 25 to 19 days) (figure
2). The BG assay produced positive results sooner than any
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other conventional diagnostic method ( , by multigroupP ! .001
comparison). BG positivity preceded positive culture and/or
histopathology results in 4 (80%) of 5 cases with positive BG
and positive microbiology or histopathology results (median
time between fever onset and positive culture or histopathology
results, 1 day; range, 0–31 days; ). It preceded minorPp .12
radiological CT signs in 14 (70%) of 20 cases with positive BG
assay results and minor radiological criteria of IFI (median time
between fever onset and positive radiological findings, 4 days;
range, 0–43 days; ). It preceded major radiologicalPp .005
signs in 15 (100%) of 15 cases with positive BG assay results
and major radiological criteria of IFI (median time between
fever onset and positive radiological findings, 13 days; range,
0–51 days; ). It preceded diagnosis by EORTC/MSGP ! .001
criteria in 18 (90%) of 20 cases with positive BG assay results
and EORTC/MSG criteria of proven or probable IFI (median
time between fever onset and EORTC/MSG criteria, 7.5 days;
range, 0–51 days; ). Empirical antifungal therapy wasP ! .001
initiated at a median time between fever onset and positive
radiological findings of 1.5 days (range, 0–10 days) after fever
onset ( [NS], vs. BG assay result). WhenPp not significant
IA and IC were analyzed separately, the median time from fever
onset to first positive BG assay result was 0 days (range, 25
to 19 days) and 2 days (range, 1 to 16 days), respectively; to
minor radiological signs was 2.5 days (range, 0–43 days; Pp
, vs. BG assay result) and 10.5 days (range, 0–23 days;NS
, vs. BG assay result), respectively; to major radiologicalPp .03
signs was 9 days (range, 0–43 days; , vs. BG assay result)Pp .03
and 19 days (range, 2–51 days; , vs. BG assay result),Pp .004
respectively; and to diagnosis by EORTC/MSG criteria was 3
days (range, 0–43 days; , vs. BG assay result) and 16Pp .004
days (range, 0–51 days; , vs. BG assay result) days,Pp .004
respectively.
Kinetics of BG antigenemia. In the 19 proven or probable
IFI cases with 2 BG measurements 7 pg/mL, the BG peak
value (median result value, 22 pg/mL; range, 8–111.5 pg/mL)
was reached a median of 10 days (range, 25 to 46 days) after
fever onset as first sign of IFI. In patients with IA, the BG peak
value (median peak value, 18 pg/mL; range, 8–51 pg/mL) was
measured a median of 3 days (range, 25 to 25 days) after
fever onset. In patients with IC, the BG peak value (median
peak value, 24 pg/mL; range, 10–111 pg/mL; , vs. thePpNS
IA group) was measured a median of 12 days (range, 1–46 days;
, vs. the IA group) after fever onset. Of note, recoveryPpNS
from neutropenia occurred within a median of 11 days (range,
6 to 54 days) after fever onset. Among 12 patients with a
follow-up of BG measurements 110 days after initiation of
antifungal therapy, BG antigenemia became negative or re-
mained !50 pg/mL in 10 patients who responded to treatment
and increased and remained 150 pg/mL in 2 patients who did
not respond to therapy (figure 3).
DISCUSSION
Investigations using different BG assays have reported sensi-
tivity of 55%–100%, specificity of 87%–93%, PPV of 40%–
84%, and NPV of 75%–100% [19–22]. Differences in study
design (case-control vs. population studies, number of cases
with proven or probable IFI [8–20 cases in population studies],
proportions of IA/IC and other IFIs, case-mix of neutropenic
and nonneutropenic patients, and antifungal prophylaxis) high-
light the need for further investigations.
We investigated the usefulness of a systematic monitoring of
BG antigenemia in neutropenic adult patients with acute leu-
kemia who did not routinely receive antifungal prophylaxis.
During 190 prolonged neutropenic episodes, 32 proven or
probable and 30 possible IFIs occurred. The best diagnostic
performance in proven or probable IFI was obtained with 2
consecutive positive BG assay results (ROC area under the
curve, 0.87); a cutoff of 2 BG measurements 7 pg/mL pro-
vided the best efficiency (89%). Per neutropenic episode and
per febrile episode analyses showed similar results. The spec-
ificity of the BG assay in documented bacteremia was excellent
(96%). This result contrasts with the high rates of false-positive
BG assay results (14 [56%] of 25) reported elsewhere among
bacteremic patients [23].
Of interest, all of the false-positive BG assay results (4%)
were observed in patients with gastrointestinal fungal coloni-
zation and/or mucositis who received empirical antifungal ther-
apy for persistent fever, suggesting an occult IFI at an early
stage. A case report has described false-positive BG assay results
in 6 patients receiving treatment with amoxicillin–clavulanic
acid [27]. A recent in vitro investigation suggests that the
amounts of BG detected in in vivo achievable concentrations
of contaminated antibiotics are negligible [28]. The low rate
of false-positive BG assay results in our study does not allow
us to draw any conclusion about the possible role of contam-
ination with BG of antibacterials given at time of blood sam-
pling. False-negative results were observed in 11 patients with
proven or probable IFIs. Three of these patients were receiving
antifungal prophylaxis, and 3 were receiving empirical anti-
fungal therapy. Prompt initiation of antifungal therapy may
result in false-negative results of circulating fungal markers, as
reported elsewhere for galactomannan [35]. The test reactivity
reflects the species-specific BG content of the cell wall in dif-
ferent fungi, which might explain false-negative results—for
example, in Candida species other than Candida albicans [36].
In the secondary analysis including proven, probable, or pos-
sible IFI, the efficiency of 2 consecutive BG values 7 pg/mL
was 75%. Major issues about the accuracy of the EORTC/MSG
classification of possible IFI as a diagnostic gold standard have
been raised [33, 37]. The revision of EORTC/MSG criteria may
provide an improved reference standard for the evaluation of
new diagnostic tests [37].
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The study of the BG kinetics in patients with proven or
probable IFI showed that BG levels were 7 pg/mL very early
(in the time window during which empirical antifungal therapy
is recommended) and preceded other diagnostic criteria, as
reported elsewhere [20, 21]. Because radiology cannot be per-
formed as frequently as blood sampling can, it is possible that
the value of radiology for the early diagnosis of IFI is under-
estimated. In patients with proven or probable IFI and 110-
day BG follow-up after initiation of antifungal therapy, BG
levels were !50 pg/mL in those responding to antifungal ther-
apy, whereas they remained 150 pg/mL in those not responding.
However, the limited data set does not allow any firm assess-
ment of the role of BG in the follow-up of IFI.
The small number of proven or probable IFIs is a common
limitation of population studies of consecutive patients with
similar risk profiles (i.e., prolonged neutropenia). However,
only this experimental design provides an estimation of the
prevalence of IFI in the target population and allows an as-
sessment of PPV and NPV by use of a diagnostic test. Moreover,
major methodological issues have been recently raised about
case-control studies for the assessment of new fungal markers
[38]. The close monitoring of BG levels and the balanced pro-
portions of IA and IC episodes occurring in the absence of
routine antifungal prophylaxis are strengths of our study, which
is aimed at evaluating a test that detects both types of IFI.
However, the lack of data on the performance of the BG assay
in candidemia without dissemination, in IFI due to fungi other
than Aspergillus and Candida species and in allogeneic hema-
topoietic stem cell transplant recipients are limitations. More-
over, this observational study was not designed to assess the
cost-effectiveness of the high number of BG tests required for
systematic monitoring.
In summary, monitoring BG antigenemia in neutropenic pa-
tients with acute leukemia is useful for the diagnosis of IFI.
Early positivity and excellent specificity suggest that detection
of BG antigenemia may support the decision to promptly start
empirical antifungal therapy in persistently febrile neutropenic
patients. However, the high proportion of single false-positive
results highlights the need to immediately confirm a positive
result by testing a second sample. Because the sensitivity of the
BG assay is limited, a test result negative for antigenemia needs
to be combined with the usual diagnostic tools (cultures, im-
aging, and histopathology) in the consideration of whether to
postpone empirical antifungal therapy. A noncomparative pilot
study has shown that a preemptive strategy combining mea-
surement of circulating galactomannan, imaging, and micro-
biological examination may improve the efficiency of manage-
ment by reducing the empirical use of antifungal agents [39].
The combination of BG assessment with species-specific tests
might further improve the diagnostic performance [20, 40].
The inclusion of BG assessment in the revised EORTC/MSG
definitions is being considered [37]. Studies are needed to con-
firm BG interpretation criteria (e.g., 2 BG measurements 7
pg/mL), performance in different clinical settings, and useful-
ness for follow-up. The assessment of the efficiency of com-
bining BG monitoring with traditional diagnostic tools in pre-
emptive management strategies needs further investigation.
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